Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Investor Presentation (January 2025)
16 slides from Koru Medical Systems's investor presentation, Jan 13, 2025
Slide 1: KORU Medical Systems Corporate Overview
KORU MEDICAL SYSTEMS A Global Leader in Large- Volume Subcutaneous Drug Delivery Nasdaq: KRMD Corporate Overview January 2025
Slide 2: Forward-Looking Statements
"== Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 regarding our expectations for future performance, including but not limited to our preliminary financi
Slide 3: Our Company
Our Company We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic More Time For What Matters Most KORU's Freedom Infusion System is a global leader in large-volume (>10mL) drug delivery Capitalizing on the ongoing shift from intravenous
Slide 4: KORU at a Glance
Our Company KORU at a Glance FY2024 REVENUES $33.7M' Domestic Core FREEDOM INTEGRATED INFUSION SYSTEM International Core 70+ Global Patents Hi Novel Therapies DRUG CLEARANCES / REGISTRATIONS 8 Drugs / 36 Countries First Subcutaneous Drug Clearance 2010 Freedom Infusion System sales for Id collaborat
Slide 5: Our Company: Freedom Infusion System
Our Company KORU’s Freedom Infusion System Mechanical Pumps ~20% of revenues of tax Freedem60° FreedemEDGE INFUSION SYSTEM INFUSION SYSTEM al. Customizable Consumables % ~80% of revenues . Simple, Easy-to-use, Freedom Integrated Infusion 8 On-label 2M+ annual infusions, Reusable mechanical SC drugs!
Slide 6: SC Landscape
SC Landscape Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities Primarily SClg Drugs with KORU Primarily Oncology Drugs [ Freedom Infusion System } f with Manual Push Syringe ] gormanon Hifentre: eumucann.iaib HYavia Cuvitru cutaquig & 0% s
Slide 7: KORU is Well Positioned to Capitalize on the Expanding SC Market
KORU’s Opportunity KORU is Well Positioned to Capitalize on the Expanding SC Market Opportunity Market Proven Freedom Infusion System Proven system with 15+ years on market; 2M+ infusions annually, underlying market growing 8-9%' Simple, reusable and fully reimbursed system with 97% adherence rate a
Slide 8: $2.7B Total Addressable Market Opportunity
KORU’s Opportunity $2.7B' Total Addressable Market Opportunity with Growing SClg Market and Expansion to New Drug Therapies Today Tomorrow Beyond Current and Near-Term Revenue Growth Opportunities 8 SC Drugs Currently on 9 Active Collaborations to add New KORU’s Future Opportunities in KORU’s Freedo
Slide 9: Strategic Growth Pillars
KORU’s Opportunity Strategic Growth Pillars Add New Drugs on Label Through Novel Therapies Pipeline 3 ~$2.2B TAM! 5 new SC Drugs expected to be commercialized and added to KRMD label by 2027 Expand Internationally 2 ~$265M TAM! 10% market share, growing at or above market rates (8-9%)? with multiple
Slide 10: Global Ig Business Drives Annual Recurring Revenue Base
KORU’s Opportunity Global Ig Business Drives Annual Recurring Revenue Base Global Patient Base @ \ Current 510k Clearances 40k Patients using the KORU ant =| 8 SClg drugs from 5 major Freedom Infusion System today, pharmaceutical manufacturers representing 2M+ annual cleared for use on the KORU recu
Slide 11: Active Pharmaceutical Collaborations Lead to $2.7B TAM
————— 0 KORU’s Opportunity Active Pharmaceutical Collaborations Lead to $2.7B' TAM 15 Total Opportu S 6 Commercial Opportunities by 2026 $2.7B! Addressable Market Combined Immunology New Indications/New Devices Drug Trial Expected KRMD Patient : Asset Phase Next Step Clearance” Population (000s) Opp
Slide 12: Financial Highlights
Financials & Outlook Financial Highlights 2024 Revenue* $33.7M; 18% y/y growth 14.5% Revenue CAGR* Revenue ($M) More than tripled size of Company in 10 years $375 Cash Flow Positive in Q4 2024* Q $33.7" FY24 cash burn of <$2M, a 67% improvement from '23-'24 Cs) $30.0 esha Cash & Cash Equivalents* .
Slide 13: Financial Profile
Financials & Outlook Financial Profile EBITDA Margin +15%> Near Term Accomplishments $100M Revenue 4Q24 Cash Flow Positive’ Accelerated Double-Digit Revenue CAGR 18% FY24 Revenue Growth! Gross Margins >65% Gross Margins 62-63%? +330-340 bps vs 2023 67% FY24 Cash Burn Improvement! KE RU 1 ssor press
Slide 14: Key 2025 Milestones
Financials & Outlook Key 2025 Milestones Financial Targets! + Double-digit revenue growth + Operational cash flow breakeven for FY2025 + Increased operating leverage Adding New Drugs to Label through Novel Therapies Pipeline * 3new pharmaceutical collaborations + 510k submission Rare Disease Drug fo
Slide 15: Experienced Pharma and MedTech Leadership Team
Our Company Strong Foundation; Experienced Pharma and MedTech Leadership Team Focused on Execution 44,000 sq. ft. Facility: + Class 8 cleanrooms . Controlled manufacturing envi . R&D laboratory space + In-house distribution center ISO 13485/MDSAP/EU MDR Certified Quality Management Systems Successfu
Slide 16: Investment Highlights
KORU Medical Investment Highlights K@RU Macro tailwinds driving adoption of subcutaneous therapy; 18+ large-volume SC drugs in development by major Pharma companies in multiple indications Double-digit growth across all businesses; Domestic Core, International Core, and Novel Therapies Strong underl
KORU Medical Systems — Investor Presentation (January 2025) on 6ix